David Malcom Rodman, Nivalis Therapeutics, Inc.'s Exec Vice President and CMO, recently acquired 12,236 shares of the company. The buys took place at prices ranging from $0.00 to $7.96 per share, on dates ranging from October 03 to October 04, 2016. Rodman now owns 12,236 shares of the company. Rodman operates out of Boulder, CO. Some additional info was provided as follows:
Represents shares issued on settlement of restricted stock units ("RSUs") granted to the reporting person upon vesting of such RSU's.
Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person to cover tax obligations in connection with the vesting of RSUs.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices
ranging from $7.95 to $8.00, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.
Represent fully vested RSUs. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal quarterly installments on the first day of each calendar quarter commencing July 1, 2016.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Nivalis Therapeutics, Inc. makes a similar move, sign up!
Other recent filings from the company include the following:
Securities to be offered to employees in employee benefit plans - June 21, 2018
Departure of Directors or Certain - June 14, 2018
Nivalis Therapeutics, Inc. just filed a prospectus, suggesting it plans to soon issue some securities - June 11, 2018
Entry into a Material Definitive - June 11, 2018